Skip to main
CYBN
CYBN logo

Cybin (CYBN) Stock Forecast & Price Target

Cybin (CYBN) Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Cybin Inc is advancing its clinical-stage neuropsychiatric programs with notable commercial readiness efforts, positioning itself strategically for scalability in interventional psychiatry. The company's strong clinical execution and financial enhancements have established a solid foundation ahead of pivotal clinical readouts expected in 2026, reinforcing confidence in its therapeutic advancements. Additionally, the completion of enrollment in the Phase 2 CYB004 generalized anxiety disorder trial and continued progress in the Phase 3 CYB003 major depressive disorder program underscore Cybin's commitment to delivering innovative treatments for mental health issues.

Bears say

Cybin Inc's stock faces a negative outlook primarily due to the risks associated with developing neuropsychiatric therapies, where trial failures can arise from various unforeseen issues. The company has experienced a reduction in its discounted cash flow (DCF) valuation based on dilution from recent fundraising efforts, which has led to a downward adjustment of its price target. Additionally, unresolved concerns regarding the safety, efficacy, and regulatory approval of Cybin's psychedelic compounds further undermine confidence in the potential success of its product pipeline.

Cybin (CYBN) has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Cybin and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Cybin (CYBN) Forecast

Analysts have given Cybin (CYBN) a Strong Buy based on their latest research and market trends.

According to 3 analysts, Cybin (CYBN) has a Strong Buy consensus rating as of Nov 26, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $45, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $45, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Cybin (CYBN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.